Craig Helm, MD
Ophthalmology · Valencia, CANPI 1588678791
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,783 of the $4,249 with a category attached, or 89.0%. It is spread thinly across 25 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $928 and has fallen 53.0% since, to $436 in 2025.
Across 142 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$684
- NEW World Medical,inc.$554
- Carl Zeiss Meditec USA, Inc.$479
- Alcon$456
- Johnson & Johnson Vision Care, Inc.$435
- Sun Pharmaceutical Industries Inc.$255
- plus $1K from 19 others
Across 2 payments — averaging $30,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$60K
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$3,78389%
- Other$44010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $684 |
| NEW World Medical,inc. | 10 | $554 |
| Carl Zeiss Meditec USA, Inc. | 2 | $479 |
| Alcon | 22 | $456 |
| Johnson & Johnson Vision Care, Inc. | 8 | $435 |
| Sun Pharmaceutical Industries Inc. | 9 | $255 |
| Dompe US, Inc. | 7 | $221 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $171 |
| Rxsight Inc | 6 | $148 |
| Bausch & Lomb Americas Inc. | 5 | $105 |
| Harrow Eye, LLC | 3 | $101 |
| Novartis | 4 | $67 |
| Thea Pharma Inc. | 3 | $63 |
| Aerie Pharmaceuticals, Inc. | 3 | $60 |
| Oyster Point Pharma, Inc. | 2 | $60 |
| Amgen(2 entities) | 4 | $60 |
| Shire North American Group Inc | 4 | $59 |
| Biotissue Holdings Inc. | 3 | $57 |
| Sight Sciences, Inc. | 2 | $53 |
| Glaukos Corporation | 1 | $52 |
| Tarsus Pharmaceuticals, Inc. | 2 | $33 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $28 |
| Omeros Corporation | 1 | $17 |
| Coopervision Inc. | 1 | $17 |
| Tearlab Corp | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLARUS 500$440
- Acuvue$213
- Kahook Dual Blade$105
- Clearpath$105
- Ahmed Glaucoma Valve$105
- Streamline$105
How this compares
$4,249 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 54 | $2,269,137 |
| RestasisCyclosporine | 87 | $92,603 |
| XiidraLifitegrast | 61 | $87,636 |
| Cyclosporine | 69 | $35,658 |
| Prednisolone Acetate | 678 | $21,153 |
| LumiganBimatoprost | 31 | $20,834 |
| Difluprednate | 219 | $16,182 |
| Bromfenac Sodium | 73 | $15,497 |
| ProlensaBromfenac Sodium | 46 | $15,449 |
| MoxifloxacinMoxifloxacin Hcl | 555 | $11,455 |
| ZirganGanciclovir | 20 | $9,408 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 373 | $7,118 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $5,475 |
| Travoprost | 22 | $4,220 |
| Latanoprost | 368 | $4,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $221 | $2,269,13754 claims |
| AbbVieRestasis, Lumigan | $684 | $113,437118 claims |
| Bausch & Lomb Americas Inc.Xiidra, Zirgan | $105 | $97,04481 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $171 | $18,34162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Valencia
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.